Wednesday, December 21, 2011

Antiaging World: Stem Cell Extracts and Skin Care

Antiaging World: Stem Cell Extracts and Skin Care BY DRJOE  

In a previous post, “Stem Cells and Anti-Ageing: Looking and Feeling Your Best” we touched on the growing trend in the field of aesthetics of the use of stem cells for treating aging skin. This involves harvesting stem cells from fat and then subsequently injecting the stem cells into wrinkled or damaged skin.

While injections of collagen and other fillers can provide excellent results these treatments are not permanent and need to be periodically repeated.  Use of stem cells provides a longer lasting solution to aging skin.

Another option of treating aging or damaged skin with stem cells is now available: topical application of stem cell extracts.

International Stem Cell Corporation has discovered a new class of pluripotent stem cells called parthenogenic stem cells.  Parthenogenic stem cells have similar characteristics of embyronic stem cells.  Parthenogenic stem cells do not, however, involve the destruction of an embryo avoiding the controversy and ethics surrounding that practice.

Pluripotent stem cells have the ability to differentiate or turn themselves into any cell needed by the body.  In skin they have the ability to become the cells that produce proteins like collagen and elastin which are necessary for healthy functioning and healthy appearing skin.  In the case of stem cell extracts, the stem cells are cracked open and the proteins and peptides within the stem cells are extracted and used to make a topical skin cream.

Please click here to read the complete article

Thursday, December 15, 2011

Fox News: Stem Cell Cream Shows Benefits Similar to Collagen Injections



Could a stem cell skin care line be coming to a store near you?

Researchers from the International Stem Cell Corporation said they have discovered a new class of pluripotent stem cells that have the same characteristics as embryonic stem cells – but don’t require destroying human embryos.

Dr. Simon Craw, vice president of the International Stem Cell Corporation, said extracts from these stem cells—called parthenogenetic stem cells—have shown benefits regarding skin care.

The scientists stumbled upon the discovery while doing stem cell research for the treatment of Parkinson’s disease.  They essentially cracked open the cells and removed the proteins and peptides from the inside to use as part of a mixture for a topical skin cream.

Wednesday, December 7, 2011

Lifeline Skin Care Products Reviewed on FOX News

Lifeline Skin Care products were featured in a segment about the “most innovative” products from the 2011 International Spa Association trade show.  FOX-19 beauty expert Paula Provenzano has been using Lifeline Skin Care herself.  And her review?  “I am loving this … it’s awesome!”

Tuesday, November 15, 2011

International Stem Cell Says Q3 Revenues Rise on Skin Care Line Success by Deborah Terescu

International Stem Cell Corp (ISCO) (OTCBB:ISCO) announced Tuesday that third quarter revenue soared as the stem cell tech company continues to advance its subsidiary Lifeline Skin Care (LSC).
Lifeline's skin care line is based on International Stem Cell's core proprietary technology, parthenogenesis, which results in the creation of human stem cells from unfertilized eggs, avoiding the ethical issue associated with the destruction of viable human embryos.
The first two products of the line, a Day Serum and a Night Serum, which were launched late last year, both contain extracts from stem cells which, in combination with vitamin complexes, provide rejuvenating effects, including improvement in skin tone and elasticity, as well as the appearance of fine lines and wrinkles.
The subsidiary announced last week two overseas distribution deals for the products, agreeing to distribute the products in the United Arab Emirates through a partnership with facial plastic surgeon, Dr. Gregory S. Keller of California, and engaging Dr. K. McIsaac to distribute Lifeline's products in Australia and New Zealand.
Parent company International Stem Cell Corp, which is focused on the therapeutic applications of human parthenogenetic stem cells, also holds subsidiary Lifeline Cell Technology (LCT), which produces and markets specalized cells for therapeutic research.
For the three months to September 30, 2011, ISCO reported revenue of $0.84 million, more than double the sales in the same period of last year, driven by strong sales from the initial launch of Lifeline Skin Care, which began operations in the fourth quarter of 2010.
In addition, the company said that steady growth in sales from ISCO’s other subsidiary, Lifeline Cell Technology, also contributed to the boost in revenue. 
ISCO continues to invest in the development of new technologies, products and channels of distribution.
For the quarter, development expenses, excluding cost of sales, were $3.60 million, an increase of 15 percent compared to the third quarter of 2010, reflecting increased research and development activities on therapeutic programs, and new product development for both subsidiaries, the company said.
“We are pleased with the rapid growth in sales of our two subsidiaries, LSC and LCT. Together, these business units are providing much-needed capital to help support our growth as well as the research leading to the development of new stem cell technologies and products,”said co-Chairman and CEO, Dr. Andrey Semechkin.
Aside from the skin care progress, during the latest quarter, ISCO has reported several operational developments, including the successful completion of the first series of preclinical trials of its neuronal cells derived from human parthenogenetic stem cells (hpSC).
The company said the cells were able to survive in the brains of mice without giving rise to tumours, representing a key milestone towards possible therapeutic applications of hpSCs, including the treatment of Parkinson's disease.
ISCO's Lifeline Cell Technology subsidiary also began selling products through new distribution channels in Japan, Korea, Singapore, Malaysia and Indonesia, expanding its business throughout Asia.
In addition, Lifeline Skin Care launched a new sales channel to resorts and destination spas.
Looking forward, president and COO, Kurt May, added:"Our focus continues to be on maximizing the performance of our operating subsidiaries, advancing the development and commercialization of our therapeutic products and strengthening our organization and operating systems to accommodate our anticipated rapid and significant growth.”
ISCO, with $2.58 million of cash and equivalents at the end of the quarter, said net loss was narrowed during the period to $2.67 million, or three cents per share, from $3.03 million, or four cents per share, a year earlier.

Thursday, November 10, 2011

International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care

International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline's products in Australia and New Zealand under Lifeline's own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company's website www.lifelineskincare.com.

The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.

"I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report," said Dr. Keller. "Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they've seen are amazing."
Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.

"In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand."

Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin's own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Wednesday, November 2, 2011

Seeking Alpha Article: 3 Contenders To Be The First Profitable Stem Cell Company by Ryan Pollock


Seeking Alpha is a stock market news and financial analysis website, including free earnings call transcripts, investment ideas and ETF & stock research written by finance experts. Ryan Pollock recently initiated coverage on International Stem Cell Corporation (ISCO).  Although the views and opinions are Mr. Pollock’s own and not necessarily those of ISCO, we thought you would be interested in his insights about our company.

To read the complete article 3 Contenders To Be The First Profitable Stem Cell Company, please click HERE

Wednesday, October 12, 2011

Patrick Cox's Breakthrough Technology Alert: International Stem Cell Corp. Progressing Despite Incompetent MSM

agorafinancial.com | contact us | login

October 11, 2011

International Stem Cell Corp. Progressing Despite Incompetent MSM

Dear Breakthrough Technology Alert Reader,
"American journalism (like the journalism of any other country) is predominantly paltry and worthless. Its pretensions are enormous, but its achievements are insignificant."

Last week, an article by Rob Stein appeared in The Washington Post titled "Scientists Report Possibly Crucial Advance in Human Embryonic Stem Cell Research." Stein, whose credentials include science editor positions at NPR and The Washington Post, describes the use of cloning techniques to turn oocytes, immature eggs, into embryonic cells. The first one-sentence paragraph is as follows:
"Scientists reported Wednesday that for the first time, they had used cloning techniques to generate embryonic stem cells containing the genes of specific patients."

Frankly, I don't know what that sentence means. Somatic cloning of stem cells has been going on for years at places such as the Harvard Stem Cell Institute and the University of California San Francisco. It's not a particularly difficult thing to transfer adult DNA into an embryonic stem cell. Maybe the researchers said that it was the first time that "they" had used cloning techniques to make ESCs and the writer misinterpreted their statements. I have no idea.

Moreover, that sentence includes the word "patients." There were no patients involved in the study. It was a laboratory demonstration of a cloning technique in which DNA from mature cells is transferred into immature eggs, oocytes. Then, the oocytes transformed into stem cells with the implanted genes. The interesting thing about the procedure, which you can access here, is that the DNA from a normal cell, from two parents, was added to a cell with only a mother's genes.

This resulted in a cell with the DNA of three people -- a triploid cell. While fascinating, it also raises all kinds of scientific and safety issues. We have no idea what triploid cells would actually do if they were implanted in a patient. With extra haploid matching points, they might even be immunocompatible with no one.

I do, however, have a great script idea if somebody with money would like to hear the pitch. I'm thinking Species meets Mommie Dearest. Regardless, the possibility that triploid cells will be therapeutically useful in the foreseeable future is very low.

This brings me to the real flaw in the story. Read the second sentence/paragraph:
"The step marks a possibly pivotal advance toward the long-sought goal of creating stem cells that could be used to treat many major diseases, because they would not be rejected by patients' immune systems."

Balderdash. There are at least two solutions already available for dealing with immune rejection -- induced pluripotent stem cells (iPSCs) and human parthenogenic stem cells (hpSCs).

The iPS cell technology uses an individual's own cells to create cells that are functionally equivalent to embryonic stem cells. These would be compatible with the donor. The other solution is the human parthenogenic stem cells developed by International Stem Cell Corp. (OTCBB:ISCO). These, scientists believe, will solve the immune rejection problem on a mass-market basis.

ISCO long ago demonstrated that they have made the "pivotal advance" using oocytes, to which the Post article refers. ISCO scientists discovered and patented the techniques that successfully create human parthenogenic stem cells (hpSCs), which can be programmed to become any other cell type. With ISCO's cell banks, which will match the various HLA profiles of the human species, the immune rejection problem will be solved for the vast majority of the human race.

You will recall from my recent issue about ISCO that the company has already begun collecting oocytes to create these parthenogenic cells lines. It does so with complete approval of regulatory and ethical agencies.

As you know, it took ISCO many years and millions of dollars to accomplish their technological breakthrough. Interestingly, it had previously been done, apparently in an accidental and nonreproducible manner. Stem cell scientist Woo Suk Hwang of Seoul University announced in 2004 that he had produced a stem cell line derived from an embryonic human clone. Later, it was discovered that Hwang did not have a cloned stem cell line. He had a parthenogenic stem cell line.

Though Hwang was disgraced, the irony is that cloned stem cell lines are far easier to produce than hpSC lines. I don't understand all the details about what he did, wrong or right. The irony is this, however: If he had presented his stem cells as hpSCs, he might have been acclaimed a scientific hero, instead of the super-villain he is considered today.

The Washington Post article goes on to cite the usual stem cell controversies. Those opposed to ESC research have voiced opposition to the triploid stem cell technology when asked. They believe the triploid cells are embryonic stem cells. Since they are, in a sense, fertilized, that may be true. It's not at all clear, though, that they could develop into an embryo. I doubt it.

Also, the fact that some fertility therapy patients were paid well for oocytes unneeded in the fertilization process has caused serious concern among feminist commentators. They are seriously concerned. Seriously.

The big point, however, is that this article badly misrepresents the state of the science. ISCO scientists have long had the ability to create pluripotent stem cells using oocytes. More to the point, cells made using their process have none of the ethical issues of these triploid cells. They are not fertilized and cannot become embryos. They require no genetic manipulation. No foreign DNA is inserted into them. The company does not pay for oocytes and has followed every ethical guideline acquiring them.

The Wall Street Journal apparently picked up on the "breakthrough" story and helped spread the disinformation, as did other news outlets and bloggers. I'm not, per se, a journalist, but if I were writing for a nationally read publication that purports to present science accurately, I would have started by checking around to see if there were other perspectives on stem cells from parthenogenic oocytes.

In fact, I did a simple Google search using key words "parthenogenic" (or "parthenogenetic"), "stem" and "cell." The first page yielded this link to ISCO's description of their human technology.

Then, looking around the site, we find a list of respected scientific partners who are assisting in further research on ISCO's hpSCs, as well as some of their research areas.

They include:

Novocell Inc., San Diego, Calif., endocrine pancreas cells.
University of California, San Francisco, Calif., hepatocyte cells.
University of California, Irvine, Calif., retinal pigment epithelium.
University of Wurzburg, Germany, neuronal cells.
The Scripps Research Institute, La Jolla, Calif., characterization of human parthenogenetic stem cells.

None of these organizations is inaccessible. You can find their phone numbers on the innerwebz, and it has been my experience that scientists are more than happy to tell journalists what's really going on. Oh, well.

Having spent so much time in debunking mode, now I feel like I ought to at least bring you up-to-date on some new developments at ISCO. Several important events have, in fact, occurred lately.

ISCO to Expand Cosmeceutical Product Lines

One, ISCO has been perfecting the process of growing and preserving the active ingredient in parthenogenic stem cells used for their cosmeceutical skin care product line. As a result, they've been able to stockpile enough of the growth factors found in stem cells to allow additional marketing efforts. In the past, availability of product has limited those efforts.

Moreover, the company has announced development of several new skin care products, including one designed to work on the sunken area under the eyes. The skin care line, while not cosmically meaningful, is doing very well for the company and is on track to fund serious work, such as ISCO's liver cell science.

Also, ISCO has brought in an experienced corporate executive to help move the company forward. Dr. Andrey Semechkin, currently CEO, will become co-chairman. Kurt May, currently senior vice president, will take the helm as president and COO.

From the press release:
"Prior to joining ISCO, Mr. May was a senior executive with GTE Corp. and with PriceSmart Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and assistant dean of UCSD's Rady School of Management from 2005-09.

"During his tenure as PriceSmart's chief operating officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability and expanding staff from 356 to more than 4,200.

"'In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success,' said Kenneth Aldrich, co-founder and co-chairman of ISCO."
Yours for transformational profits,

Patrick Cox


Please note: We sent this e-mail to: PATRICK COX because you subscribed to this service.
To log in to the website, please visit http://breakthroughtechnologyalert.agorafinancial.com/ and login using your permanent username and passwords below:

Please note that if you have multiple e-mail addresses associated with this account, the username and password above may be blank. To cancel by mail or for any other subscription issues, write us at:

Order Processing Center | Attn: Customer Service | P.O. Box 960 | Frederick, MD 21705 USA
           
Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice.
We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
©2011 Agora Financial, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web) , in whole or in part, is strictly prohibited without the express written permission of Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202.

Wurzburg, Germany, neuronal cells.
The Scripps Research Institute, La Jolla, Calif., characterization of human parthenogenetic stem cells.

None of these organizations is inaccessible. You can find their phone numbers on the innerwebz, and it has been my experience that scientists are more than happy to tell journalists what's really going on. Oh, well.

Having spent so much time in debunking mode, now I feel like I ought to at least bring you up-to-date on some new developments at ISCO. Several important events have, in fact, occurred lately.

ISCO to Expand Cosmeceutical Product Lines

One, ISCO has been perfecting the process of growing and preserving the active ingredient in parthenogenic stem cells used for their cosmeceutical skin care product line. As a result, they've been able to stockpile enough of the growth factors found in stem cells to allow additional marketing efforts. In the past, availability of product has limited those efforts.

Moreover, the company has announced development of several new skin care products, including one designed to work on the sunken area under the eyes. The skin care line, while not cosmically meaningful, is doing very well for the company and is on track to fund serious work, such as ISCO's liver cell science.

Also, ISCO has brought in an experienced corporate executive to help move the company forward. Dr. Andrey Semechkin, currently CEO, will become co-chairman. Kurt May, currently senior vice president, will take the helm as president and CEO.

From the press release:
"Prior to joining ISCO, Mr. May was a senior executive with GTE Corp. and with PriceSmart Inc., and the founder and CEO of a privately owned biotech company, Psynomics, based on medical technology derived from the University of California, San Diego. Mr. May served as a faculty member and assistant dean of UCSD's Rady School of Management from 2005-09.

"During his tenure as PriceSmart's chief operating officer, Mr. May led the company from startup to growth over three years that included establishing 22 stores in 11 countries, reaching annual revenues of more than $500 million, achieving profitability and expanding staff from 356 to more than 4,200.

"'In addition to its therapeutic programs, ISCO is dedicated to building its revenue-generating subsidiaries to high levels of profitability. We view Mr. May's commercial and entrepreneurial skills as an essential part of our business plan for success,' said Kenneth Aldrich, co-founder and co-chairman of ISCO."
Yours for transformational profits,

Patrick Cox 

Please note: We sent this e-mail to: PATRICK COX because you subscribed to this service.
To log in to the website, please visit http://breakthroughtechnologyalert.agorafinancial.com/  and login using your permanent username and passwords below:

customer number: 45650415
username:COX48935
password:21202

Please note that if you have multiple e-mail addresses associated with this account, the username and password above may be blank. To cancel by mail or for any other subscription issues, write us at:

Order Processing Center | Attn: Customer Service | P.O. Box 960 | Frederick, MD 21705 USA
           
Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice.

We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
©2011 Agora Financial, LLC. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web) , in whole or in part, is strictly prohibited without the express written permission of Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202.

Friday, October 7, 2011

International Stem Cell Subsidiary Commences New Skin Care Marketing Campaign


International Stem Cell Corporation today announced that its wholly owned subsidiary, Lifeline Skin Care, has launched a new marketing program. New promotional efforts include (1) rebranding the line to feature Lifeline's unique selling proposition; (2) creating greater consumer awareness through public relations as well as online marketing; and (3) re-marketing to existing users to strengthen brand loyalty. Research has established that the brand's proprietary stem cell technology is a critical point of difference in the skincare market, and it's also the reason to believe in the brand. New marketing materials feature the headline, "Someday, stem cells will change the world. Today, stem cells will change your skin." This messaging is now being communicated through online and traditional marketing and sales promotion materials.
The current marketing program follows six months in which little or no marketing was done by the company because initial sales that were booked in January from a December 2010 launch had far exceeded expectations and, as a result, also exceeded supplies of the unique stem cell extract that is the key ingredient in the Lifeline Skin Care products. The company has now built a substantial reserve inventory of the essential stem cell extract and has also designed new marketing programs to both minimize sudden surges in demand and permit controlled testing of new products and sales initiatives. The company has also re-engineered its quality control, logistics and customer service to deliver higher quality products and services to the consumer.
"Sales for the first two weeks of the new program were approximately 1,000 units, which is in line with our expectations and does not include any sales from pending initiatives to spas and medical clinics or international sales," said Donna Queen, Vice President of Marketing and Business Development.
"In keeping with the reporting practices of its parent company, International Stem Cell Corporation, revenue data will not be released except on a quarterly basis, but Lifeline Skin Care will continue to advise its customers and ISCO investors of new sales initiatives as a way of increasing customer awareness and referral business," said Dr. Ruslan Semechkin, President and CEO of Lifeline Skin Care. As previously announced, International Stem Cell Corporation defers all revenues associated with Lifeline Skin Care products until the 30 day right of return guarantee expires.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell(TM). ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com  .
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .
Forward-looking Statements
Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, including the expected results of enhancements in Lifeline Skin Care marketing efforts, constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, competition, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Thursday, September 22, 2011

Stem Cell Skin Cream Video: Care for Your Skin with Lifeline Skin Care

Lifeline Skin Care® (Lifeline) is a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO), a publicly traded biotechnology company which has developed a powerful and ethical new stem cell technology called “parthenogenesis”.  ISCO created Lifeline Skin Care® to further develop its discoveries that extracts from human parthenogenetic stem cells had beneficial effects on human skin cells.

International Stem Cell is focused on advancing its human parthenogenetic stem cell technology towards finding treatments for blinding diseases of the eye, liver disease, diseases of the nervous system and diabetes.

Our goal at Lifeline Skin Care® is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology and skin cream formulation technology to create the highest quality, scientifically tested and most effective skin care products.

Thursday, August 25, 2011

Video: "The Promising Cells" presented by International Stem Cell Corporation

In this video presentation, see and hear an overview of International Stem Cell Corporation (ISCO.OB). ISCO has developed a process to derive stem cells similar to Embryonic Stem Cells without the need for fertilized embryos and with minimal exposure to non-human cells. These factors provide ISC a unique leadership role in the field of regenerative cell therapy. You'll hear directly from Executive Chairman, Kenneth Aldrich. Lifeline Cell Technology and Skin Care Products, revenue generating units of ISCO are also reviewed.

This presentation was produced by Big Sky Productions, INC (BGSI.OB), Co-Executive Producers Ellis Martin and Bob Lange. contact: bigskymedia@yahoo.com


Tuesday, August 16, 2011

Lifeline Skin Care: The Science Of Stem Cells



Stem cells are immortal cells that can both proliferate (divide) and change (differentiate) into more specialized cells such as skin, liver or blood cells.  The most powerful stem cells are known as “pluripotent” because they have the potential to become any cell in the body.  The first pluripotent stem cells to be studied were embryonic stem cells, but because creating embryonic stem cells involves the destruction of a fertilized human embryo, many people have ethical concerns about the use of such cells.  To avoid any such ethical concerns, Lifeline Skin Care® uses instead a proprietary extract from a different class of pluripotent stem cells called parthenogenetic stem cells.  As a result, a user of our serum need never be concerned that a viable human embryo was damaged or destroyed to create the product.

The ability of pluripotent stem cells to divide an unlimited number of times seemingly without showing signs of aging or changing is because of a unique enzyme called telomerase.  The DNA molecules of normal cells (including some stem cells) get slightly shorter each time the cell divides, eventually reaching a point where the cell dies.  Telomerase’s job is to constantly rebuild the end of the cells’ DNA after they divide, but in normal adult tissue (except blood and certain other types of tissue in the immune system) the enzyme is not present in sufficient concentrations to stop the cells dying over time.  Only parthenogenetic and embryonic stem cells possess enough telomerase to make them effectively immortal.

The human parthenogenetic stem cells we use were created by our parent company International Stem Cell Corporation, the world leader in the use of human parthenogenetic stem cell technology to search for ways of treating human disease using stem cell technology.

To learn more about human stem cells, please visithttp://www.internationalstemcell.com/parthenogenesis.htm

Sunday, August 14, 2011

Check the Expiration Date on Your Sunscreen!

Planning on taking one more sunny vacation this summer? 

Be sure to check the expiration date on your sunscreen. They generally have a three year dating system, so they may not be effective beyond that expiration date. The chemical sunscreens (like PABA and avobenzone) are particularly unstable. 

Thursday, August 4, 2011

Why Do People Have Puffy Eyes After 40?


The reason that people 40+ have puffy eyes is not lack of sleep, it's that the fat pads under your eyes start to bulge.  Solution: use an eye cream with caffeine or rosemary, or use cool compresses.  Fat - it's the bane of our existence!  Who knew that you have fat pads under your eyes?

Here are some more helpful suggestions: http://www.wikihow.com/Cure-Puffy-Eyes

Wednesday, August 3, 2011

What Do You Expect From A Good Eye Cream?

Wow! We did a focus group on eye creams, and what was women's biggest concern (after lines and wrinkles, of course!)?? Puffy eyes! What do you expect from a good eye cream?  

Tuesday, August 2, 2011

Eat a Salad For Lunch!


According to Dr. Oz's RealAge, the same stuff that's good for your skin (leafy greens, omega-3 fatty acids and nuts) will also help prevent macular degeneration. So what does that have to do with Lifeline? International Stem Cell (Lifeline's parent company) is working on new lines of stem cells that will prevent or correct macular degeneration.

Saturday, July 30, 2011

FDA Announces New Requirements For Over-The-Counter (OTC) Sunscreen Products


Going outside today?? Check out the FDA's new guidelines on sunscreen - there is NO SUCH THING as waterproof or sweat-proof SPF. They're false and misleading claims. Wear a good sunscreen and reapply it every two hours...and have fun!

Thursday, July 28, 2011

International Stem Cell to Hold Business Update Conference Call on August 10

International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Wednesday, August 10, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). Chairman Ken Aldrich will provide an update on the business, including plans for the future development of the skin care line; animal and potential clinical trials for Parkinson's and liver diseases; and the Company's business strategy for 2011 and longer term.

Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site atwww.intlstemcell.com.

A telephone replay will be available approximately one hour after the conclusion of the call by dialing 877-660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 376367. The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Thursday, June 30, 2011

Lifeline Cell Technology’s FibroLife Media Used to Cultivate Tissue-Engineered Blood Vessels for Cytograft Tissue Engineering

International Stem Cell Corporation’s (ISCO) subsidiary, Lifeline Cell Technology (Lifeline), contributed a critical role in developing a cell culture media that is suitable to grow the blood vessels used by Cytograft Tissue Engineering. 

As seen in the American Heart Association ‘s innovative forum for late breaking science, “Emerging Science Series” webinar, Focus on Thrombosis and Vascular Biology, Cytograft’s technology has shown positive clinical results in the extensive market for vascular grafts; a market that exceeds 500,000 patients. 

Applications for this technology include vascular shunts for hemodialysis for patients with kidney disease, lower limb circulation problems and coronary artery bypass grafts. If approved in further upcoming clinical trials, Lifeline’s media will be made to clinical grade in its cGMP media manufacturing facilities.

Coverage of this important story has been reported in the following media:
Forbes 


CNN